Trials / Completed
CompletedNCT02215733
The Use of Angiotensin Receptor Blockers and the Risk of Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,165,781 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study was to assess whether angiotensin blockers (ARBs) and telmisartan in particular, are associated with an increased overall risk of the four most common cancers, namely, lung, colorectal, breast and prostate cancers. A secondary objective was to explore these effects separately for each of the four cancers and in combination with angiotensin-converting-enzyme-inhibitors (ACEIs).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ARB | other than telmisartan |
| DRUG | ACEI | |
| DRUG | Beta-blockers | |
| DRUG | Diuretics | |
| DRUG | Telmisartan |
Timeline
- Start date
- 2011-02-01
- Primary completion
- 2012-02-01
- First posted
- 2014-08-13
- Last updated
- 2014-08-13
Source: ClinicalTrials.gov record NCT02215733. Inclusion in this directory is not an endorsement.